Core Viewpoint - Haofan Bio (301393.SZ) announced changes in the use of raised funds and project completion timelines due to external policy changes and operational needs [1] Group 1: Fund Usage Changes - The project "Suzhou Haofan Bio Co., Ltd. 100kg/year peptide and protein reagent R&D and production and headquarters construction project (Phase I)" has reached a usable state, and the remaining funds will be used to supplement working capital [1] - The company plans to change the use of a total of 49,696.68 million yuan of raised funds from the "Anhui Haofan peptide reagent and pharmaceutical intermediates construction project" and "peptide and protein reagent R&D platform construction project" to the "Huaian Haofan production base construction project" [1] - The remaining funds after the changes will be used to supplement working capital, with the net amount being cash management income minus handling fees [1] Group 2: Project Completion and Timeline Adjustments - The "Anhui Haofan peptide reagent and pharmaceutical intermediates construction project" and "peptide and protein reagent R&D platform construction project" are proposed to be completed [1] - The timeline for the "Huaian Haofan production base construction project" is extended to December 2028 to ensure safe, rapid, and orderly capacity construction [1]

Group 1 - The company approved the use of idle raised funds and self-owned funds for cash management, with a maximum amount of RMB 4 billion from idle raised funds and RMB 11 billion from idle self-owned funds [1][18] - The cash management aims to improve the efficiency of fund utilization while ensuring the safety of raised funds and normal business operations [6][14] - The company will invest in high-security, liquid financial products issued by banks, securities companies, or trust companies, including but not limited to structured deposits, time deposits, and large certificates of deposit [6][8] Group 2 - The company raised a total of RMB 788.55 million through the issuance of A-shares, with a net amount of RMB 773.69 million after deducting various fees [2][24] - The company has established a special account management system for the raised funds and signed a tripartite supervision agreement with the sponsor and the bank [3][25] - The company plans to use the surplus funds from completed projects to permanently supplement its working capital, amounting to RMB 37.92 million [23][31] Group 3 - The company has completed the "Suzhou Technology R&D Center (Phase II)" and "Intelligent Warehouse Project," and the surplus funds will be used for daily operations [28][31] - The "Digital Production Base Construction Project" has been postponed to March 2026, with no changes to the investment content or total amount [32][35] - The company will continue to monitor the progress of the projects and ensure efficient use of raised funds [32][34] Group 4 - The company plans to apply for a credit limit of up to RMB 1.5 billion from banks to meet operational needs [39][40] - The credit limit will be valid for 12 months and can be used repeatedly within that period [40]